Netherlands temporarily halts AstraZeneca Covid-19 vaccine for under-60s

The Netherlands has temporarily halted the use of the AstraZeneca Covid-19 vaccine for people under the age of 60, the Ministry of Health, Welfare and Sport.

AstraZeneca, Coronavirus vaccine
Photo: Shutterstock
IANS The Hague
2 min read Last Updated : Apr 03 2021 | 10:04 AM IST

The Netherlands has temporarily halted the use of the AstraZeneca Covid-19 vaccine for people under the age of 60, the Ministry of Health, Welfare and Sport.

The decision on Friday was prompted by possible blood clotting problems as a side effect of the vaccine, reports Xinhua news agency.

Earlier on in the day, the Lareb side effects centre reported that after injecting some 400,000 doses of the AstraZeneca vaccine, five reports have been received concerning women aged 25-65 who developed thrombosis in combination with a reduced platelet count.

One of these five women died after developing an extensive pulmonary embolism within 10 days of the vaccination.

The outgoing Dutch Health Minister Hugo de Jonge said there should be no doubt whatsoever about the safety of vaccines.

"The crucial question is still whether it concerns complaints after vaccination or due to vaccination," he said in a statement, adding that "it is wise to press the pause button now as a precaution".

The Minister wrote in a letter to Parliament that he took this decision pending a further judgment by the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency.

The committee is expected to come with further information about the AstraZeneca vaccine.

Besides the Netherlands, vaccination is underway in an increasing number of countries with the already-authorised coronavirus vaccines.

--IANS

ksk/

 

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusLockdownCoronavirus VaccineCoronavirus Tests

First Published: Apr 03 2021 | 10:00 AM IST

Next Story